Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation

BackgroundSchizophrenia is likely to be a consequence of DNA alterations that, together with environmental factors, will lead to protein expression differences and the ultimate establishment of the illness. The superior temporal gyrus is implicated in schizophrenia and executes functions such as the processing of speech, language skills and sound processing.MethodsWe performed an individual comparative proteome analysis using two-dimensional gel electrophoresis of 9 schizophrenia and 6 healthy control patients' left posterior superior temporal gyrus (Wernicke's area – BA22p) identifying by mass spectrometry several protein expression alterations that could be related to the disease.ResultsOur analysis revealed 11 downregulated and 14 upregulated proteins, most of them related to energy metabolism. Whereas many of the identified proteins have been previously implicated in schizophrenia, such as fructose-bisphosphate aldolase C, creatine kinase and neuron-specific enolase, new putative disease markers were also identified such as dihydrolipoyl dehydrogenase, tropomyosin 3, breast cancer metastasis-suppressor 1, heterogeneous nuclear ribonucleoproteins C1/C2 and phosphate carrier protein, mitochondrial precursor. Besides, the differential expression of peroxiredoxin 6 (PRDX6) and glial fibrillary acidic protein (GFAP) were confirmed by western blot in schizophrenia prefrontal cortex.ConclusionOur data supports a dysregulation of energy metabolism in schizophrenia as well as suggests new markers that may contribute to a better understanding of this complex disease.

[1]  T. Sharma,et al.  The Relationship of Structural Alterations to Cognitive Deficits in Schizophrenia: A Voxel-Based Morphometry Study , 2005, Biological Psychiatry.

[2]  H. Wu,et al.  Neuron-specific enclose and myelin basic protein in cerebrospinal fluid of patients with first episode schizophrenia , 2006 .

[3]  Lina Shihabuddin,et al.  A comprehensive assessment of gray and white matter volumes and their relationship to outcome and severity in schizophrenia , 2007, NeuroImage.

[4]  W. Gattaz,et al.  The use of ASB-14 in combination with CHAPS is the best for solubilization of human brain proteins for two-dimensional gel electrophoresis. , 2007, Briefings in functional genomics & proteomics.

[5]  P. Kinnunen,et al.  Increased serum phospholipase A2 activity in schizophrenia: a replication study. , 1990, Biological psychiatry.

[6]  G. Reynolds,et al.  Increased density of glutamate/N-methyl-d-aspartate receptors in superior temporal cortex in schizophrenia , 2001, Neuroscience Letters.

[7]  John D. Storey.  A direct approach to false discovery rates , 2002 .

[8]  S. Cordwell,et al.  A proteome analysis of the anterior cingulate cortex gray matter in schizophrenia , 2006, Molecular Psychiatry.

[9]  Nanette Freedman,et al.  Cerebral glucose utilization and platelet mitochondrial complex I activity in schizophrenia: A FDG-PET study , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[10]  Luis Martí-Bonmatí,et al.  Chronic auditory hallucinations in schizophrenic patients: MR analysis of the coincidence between functional and morphologic abnormalities. , 2007, Radiology.

[11]  R. Yolken,et al.  Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress , 2004, Molecular Psychiatry.

[12]  Pat Levitt,et al.  Molecular Characterization of Schizophrenia Viewed by Microarray Analysis of Gene Expression in Prefrontal Cortex , 2000, Neuron.

[13]  Andrew L. Lemire,et al.  Deficient Hippocampal Neuron Expression of Proteasome, Ubiquitin, and Mitochondrial Genes in Multiple Schizophrenia Cohorts , 2005, Biological Psychiatry.

[14]  C. Jolly,et al.  Genomic structure and chromosomal mapping of the mouse STOP gene (Mtap6). , 1998, Biochemical and biophysical research communications.

[15]  M. Webster,et al.  Application of cDNA microarrays to examine gene expression differences in schizophrenia , 2001, Brain Research Bulletin.

[16]  A. Foster,et al.  Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia , 2006, International review of psychiatry.

[17]  C. Aston,et al.  Microarray analysis of postmortem temporal cortex from patients with schizophrenia , 2004, Journal of neuroscience research.

[18]  Paul Antoine Salin,et al.  The suppression of brain cold-stable microtubules in mice induces synaptic defects associated with neuroleptic-sensitive behavioral disorders. , 2002, Genes & development.

[19]  Elaine Holmes,et al.  Metabolic changes in schizophrenia and human brain evolution , 2008, Genome Biology.

[20]  C. Dodia,et al.  1-Cys Peroxiredoxin, a Bifunctional Enzyme with Glutathione Peroxidase and Phospholipase A2 Activities* , 2000, The Journal of Biological Chemistry.

[21]  A. Fagan,et al.  Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder , 2008, Molecular Psychiatry.

[22]  R. Thompson,et al.  Immunoreactive Aldolase C in Cerebrospinal Fluid of Patients with Neurological Disorders , 1980, Annals of clinical biochemistry.

[23]  K. Narisawa,et al.  Dihydropteridine reductase in schizophrenic patients , 1985, Psychiatry Research.

[24]  V. Haroutunian,et al.  Cortical expression of glial fibrillary acidic protein and glutamine synthetase is decreased in schizophrenia , 2008, Schizophrenia Research.

[25]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[26]  W H Wong,et al.  Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  C. Masters,et al.  Decreased phosphatidylethanolamine binding protein expression correlates with Aβ accumulation in the Tg2576 mouse model of Alzheimer's disease , 2006, Neurobiology of Aging.

[28]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[29]  M. Suaud-Chagny,et al.  Dopaminergic transmission in STOP null mice , 2005, Journal of neurochemistry.

[30]  J. Deakin,et al.  NR2B-containing NMDA receptors are up-regulated in temporal cortex in schizophrenia. , 1999, Neuroreport.

[31]  Pat Levitt,et al.  Molecular Evidence for Increased Expression of Genes Related to Immune and Chaperone Function in the Prefrontal Cortex in Schizophrenia , 2007, Biological Psychiatry.

[32]  M. Lidow,et al.  Identification of protein biomarkers for schizophrenia and bipolar disorder in the postmortem prefrontal cortex using SELDI-TOF-MS ProteinChip profiling combined with MALDI-TOF-PSD-MS analysis , 2006, Neurobiology of Disease.

[33]  Hanrong Wu,et al.  Neuron-specific Enolase and myelin basic protein in cerebrospinal fluid of patients with first episode schizophrenia. , 2006, Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban.

[34]  E. Hall,et al.  Identification and characterization of PEBP as a calpain substrate , 2006, Journal of neurochemistry.

[35]  W. Gattaz,et al.  Phospholipase A2 and the hypofrontality hypothesis of schizophrenia. , 1996, Prostaglandins, leukotrienes, and essential fatty acids.

[36]  R. Burwell,et al.  Raf kinase inhibitory protein knockout mice: Expression in the brain and olfaction deficit , 2007, Brain Research Bulletin.

[37]  M. Gerlach,et al.  Increased mRNA levels of the mitochondrial complex I 75-kDa subunit , 2006, European Child & Adolescent Psychiatry.

[38]  J. Kane.  Treatment of schizophrenia. , 1987, Schizophrenia bulletin.

[39]  W. Gattaz,et al.  Erratum: The use of ASB-14 in combination with CHAPS is the best for solubilization of human brain proteins for two-dimensional gel electrophoresis (Briefings in Functional Genomics and Proteomics (2007) vol. 6 (70-75)) , 2009 .

[40]  C. Turck,et al.  Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. , 2009, Journal of psychiatric research.

[41]  L. Kirk,et al.  [Treatment of schizophrenia]. , 1971, Ugeskrift for laeger.

[42]  H. Hwu,et al.  Linkage of schizophrenia with chromosome 1q loci in Taiwanese families , 2003, Molecular Psychiatry.

[43]  V. Haroutunian,et al.  Variations in differential gene expression patterns across multiple brain regions in schizophrenia , 2005, Schizophrenia Research.

[44]  Dorit Ben-Shachar,et al.  Mitochondrial dysfunction in schizophrenia: a possible linkage to dopamine , 2002, Journal of neurochemistry.

[45]  J. Manjón,et al.  Schizophrenia with auditory hallucinations: A voxel-based morphometry study , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[46]  T. Jahn,et al.  Die statistische Kontrolle möglicher Medikamenteneinflüsse in experimentalpsychologischen Schizophreniestudien: Ein Vorschlag zur Berechnung von Chlorpromazinäquivalenten , 1989 .

[47]  Ben Crossett,et al.  Abnormal pathways in the genu of the corpus callosum in schizophrenia pathogenesis: a proteome study , 2007, Proteomics. Clinical applications.

[48]  C. Turck,et al.  Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis , 2009, Journal of Neural Transmission.

[49]  R. Yolken,et al.  Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder , 2000, Molecular Psychiatry.

[50]  Kyla Pennington,et al.  Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: Evidence for disease‐associated changes , 2006, Proteomics.

[51]  Monte S. Buchsbaum,et al.  Cortical gray and white matter volume in unmedicated schizotypal and schizophrenia patients , 2008, Schizophrenia Research.

[52]  Peter B. Jones,et al.  Oligodendrocyte dysfunction in schizophrenia and bipolar disorder , 2003, The Lancet.

[53]  D. Welch,et al.  Breast cancer metastasis suppressor 1: Update , 2004, Clinical & Experimental Metastasis.

[54]  Ming T Tsuang,et al.  Evidence for linkage between regulatory enzymes in glycolysis and schizophrenia in a multiplex sample , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[55]  S. Hirsch,et al.  Cholecystokinin messenger RNA deficit in frontal and temporal cerebral cortex in schizophrenia , 1995, Biological Psychiatry.

[56]  R Tandon,et al.  Superior temporal gyrus in schizophrenia: a volumetric magnetic resonance imaging study , 2000, Schizophrenia Research.

[57]  H. Braak,et al.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry , 2006, Acta Neuropathologica.

[58]  J. Pierri,et al.  Gene Expression Profiling Reveals Alterations of Specific Metabolic Pathways in Schizophrenia , 2002, The Journal of Neuroscience.

[59]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[60]  D. Laifenfeld,et al.  Mitochondria, synaptic plasticity, and schizophrenia. , 2004, International review of neurobiology.

[61]  Carlo Caltagirone,et al.  The language of schizophrenia: An analysis of micro and macrolinguistic abilities and their neuropsychological correlates , 2008, Schizophrenia Research.